Chardan Capital Raises SAB Biotherapeutics Price Target to $14

Analysts boost price target on biotech company's stock

Mar. 11, 2026 at 7:07pm

Got story updates? Submit your updates here. ›

Chardan Capital analysts have raised their price target on SAB Biotherapeutics (NASDAQ:SABS) from $12 to $14, maintaining a "buy" rating on the stock. The analysts cited the company's progress in developing its proprietary Tc Bovine® platform for producing human antibody therapies.

Why it matters

SAB Biotherapeutics is a clinical-stage biotech company focused on developing fully human polyclonal antibody treatments. The Chardan Capital price target increase suggests analysts see significant upside potential in the company's technology and pipeline.

The details

In a report released on Wednesday, Chardan Capital analysts boosted their price target on SAB Biotherapeutics from $12 to $14, while reiterating a "buy" rating on the stock. The analysts cited the company's progress in advancing its Tc Bovine® platform, which uses genetically engineered cattle to generate large quantities of human antibodies. SAB Biotherapeutics is currently developing antibody therapies primarily for infectious diseases.

  • Chardan Capital released the updated price target and rating on March 11, 2026.

The players

Chardan Capital

An investment banking and securities firm that provides research coverage on SAB Biotherapeutics.

SAB Biotherapeutics

A clinical-stage biotechnology company focused on developing fully human polyclonal antibody therapeutics using its proprietary Tc Bovine® platform.

Got photos? Submit your photos here. ›

The takeaway

The Chardan Capital price target increase highlights the potential of SAB Biotherapeutics' unique antibody production platform and its pipeline of infectious disease treatments, signaling optimism about the company's future growth prospects.